Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Acepodia Biotech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
CD20-positive B-cell NHL that is persistent or progressive after having received at least 2 prior systemic therapies per NCCN guidelines
At least 1 measurable lesion according to the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 or subjects with ECOG scores of 2 with a serum albumin of \>3.5
Adequate hematologic and renal, hepatic, and cardiac function
Oxygen saturation via pulse oxygenation ≥ 92% at rest on room air
You may not be if
Prior treatment with a genetically modified cell therapy product targeting CD20
Autologous stem cell transplant within 6 weeks of informed consent or history of allogeneic stem cell transplantation
History of central nervous system (CNS) lymphoma or primary CNS lymphoma
History or presence of clinically relevant CNS disorder (e.g. epilepsy)
Clinically significant active infection
Currently active, clinically significant cardiovascular disease
Human Immunodeficiency virus (HIV) infection (however, subjects on anti-retroviral therapy for at least 4 weeks and with HIV viral loads of \<400 copies/mL are eligible), active hepatitis B infection, or hepatitis C infection
History of other malignancies with the exception of certain treated malignancies with no evidence of disease
Primary immunodeficiency disorder
Pregnant or lactating female
Any medical, psychological, familial, or sociological conditions that, in the opinion of the Investigator or Sponsor Medical Monitor, would impair the ability of the subject to receive study treatment, comply with study requirements, or understanding of the informed consent
Clareo Health | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
